(P-1229) Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

JD

Justine Dao, n/a

Debiopharm International
Lausanne, Vaud, Switzerland
CR

Christopher M. Rubino, PharmD

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
AM

Annick Menetrey, n/a

Debiopharm International
Lausanne, Vaud, Switzerland
AC

Anthony P. Cammarata, M.S.

Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
JH

Jeffrey P. Hammel, MS

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
GD

Guennaelle Dieppois, n/a

Debiopharm International
Bern, Bern, Switzerland
JN

Justyna Nowakowska, n/a

Debiopharm International
Lausanne, Vaud, Switzerland
JB

Juan Bravo, n/a

Debiopharm International
Lausanne, Vaud, Switzerland
BV

Brian D. VanScoy, B.S.

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
Stephen Hawser, PhD

CEO
IHMA Europe
Monthey, Valais, Switzerland
VN

Valerie Nicolas-Metral, PhD

Debiopharm International
Lausanne, Vaud, Switzerland
Sujata M. Bhavnani, PharmD; MS; FIDSA

Executive Vice President
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States